Table 4

Results of multivariate logistic regression analysis assessing the relationship between MAFLD and gastrointestinal conditions

OR95% CIP value
Fatty liver1.361.30 to 1.42 <0.001
Age categories
 18–44Reference
 45–641.821.74 to 1.89 <0.001
 >651.691.60 to 1.77 <0.001
Sex
 MaleReference
 Female1.131.11 to 1.6 <0.001
Race
 CaucasianReference
 African American0.860.83 to 0.89 <0.001
 Hispanic0.840.81 to 0.88 <0.001
 Asian/Pacific Islander0.760.71 to 0.81 <0.001
 Native American1.211.06 to 1.37 <0.001
 Other0.870.81 to 0.93 <0.001
Median household income
 Lowest quartileReference
 Second quartile0.860.83 to 0.90 <0.001
 Third quartile0.790.76 to 0.82 <0.001
 Highest quartile0.770.72 to 0.82 <0.001
Income quartiles
 Lowest quartileReference
 Second quartile1.051.01 to 1.08 <0.001
 Third quartile1.081.04 to 1.12 <0.001
 Highest quartile1.061.02 to 1.11 <0.001
Comorbidities
 Gastro-oesophageal reflux disease1.131.11 to 1.16 <0.001
 Hyperlipidaemia0.810.79 to 0.83 <0.001
 Smoking0.840.82 to 0.86 <0.001
 Diabetes0.900.88 to 0.92 <0.001
 Hypertension1.061.03 to 1.09 <0.001
 Obesity0.750.73 to 0.77 <0.001
 Obstructive sleep apnoea0.840.81 to 0.87 <0.001
Charlson Comorbidity Index
 0Reference
 11.471.42 to 1.53 <0.001
 21.871.79 to 1.95 <0.001
 3 or more2.402.30 to 2.50 <0.001
Inflammatory bowel disease5.024.79 to 5.23 <0.001
  • Significant values are in bold (p<0.05).

  • MAFLD, metabolic dysfunction-associated fatty liver disease.